Photo: Depositphotos
May 16, 2025, 06:13
IASLC – FDA Accelerated Approval of Emrelis for Advanced NSCLC
International Association for the Study of Lung Cancer (IASLC) posted on LinkedIn:
“FDA Accelerated Approval Alert
The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) showing high c-Met protein expression—after prior systemic treatment.
Based on the LUMINOSITY trial
• 35% overall response rate.
• Median duration of response: 7.2 months.
Why this matters for lung cancer care:
• Offers a new option for patients with high c-Met protein expression.
• Fills a treatment gap for previously treated NSCLC patients.
• Highlights the impact of biomarker-driven therapies.
More posts featuring NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 15:47
Jun 5, 2025, 15:44
Jun 5, 2025, 15:07